Expanded double negative T cells in SLE
Expanded double negative T cells in SLE
批准号:
7791807
负责人:
George C Tsokos
金额:
$43.45万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-01 至 2015-04-30
关键词:
AccountingAgeAmericanAntibioticsAttentionAutologousB-LymphocytesBiochemicalBiological MarkersCD8B1 geneCell DeathCell LineCell physiologyCellsClinicalCoculture TechniquesCytotoxic agentDataDendritic CellsDiagnosisDiseaseGenerationsHomingImmuneImmunoglobulinsImmunosuppressionIn VitroInterferon-alphaInterferonsInterleukin-17Interleukin-2Interleukin-6KidneyLupus NephritisMolecularMorbidity - disease rateNatureOrganPatientsPeripheralPopulationPredispositionProductionQuality of lifeSignal TransductionSteroidsSurfaceSystemic Lupus ErythematosusT-Cell ReceptorT-LymphocyteTestingTissuesWomanbasechild bearingcytokinecytotoxicmortalitynovelperipheral bloodpublic health relevanceresearch studyresponsetherapeutic target
中文摘要
描述(由申请人提供):系统性红斑狼疮困扰着100万至200万美国人,并与显著的发病率和死亡率有关。虽然在过去的30年里,合理使用类固醇和细胞毒性药物以及有效使用抗生素显著提高了患者的总体生存率和生活质量,但我们仍然缺乏具体的治疗方法,其中,对相关致病机制和适当的疾病生物标志物缺乏充分了解是造成这一现象的原因之一。系统性红斑狼疮(SLE)患者免疫细胞和细胞因子异常多样,包括细胞毒反应降低、活化诱导细胞死亡减少、T调节功能降低、树突状细胞功能增强、IFNA、IL-6升高和IL-2、IFN?和TNFa生产。不同的分子和生化异常可以解释几种细胞和细胞因子的异常。在外周T细胞中,扩增的T细胞从表面缺失了CD4和CD8(存在双阴性T细胞),当与自体B细胞共培养时,促进免疫球蛋白和抗双链DNA的产生。我们最近发现,SLE患者的这种糖尿病肾病T细胞群可以在体外扩增,并产生IL-17,更重要的是,产生IL-17的糖尿病肾病T细胞渗入狼疮性肾炎患者的肾组织。因此,我们提出,在SLE患者中,扩大的糖尿病肾病T细胞群产生IL-17,并参与靶器官损害。我们将在本申请中概述的实验中测试我们的论点,并将其归类为四个特定目标:在第一个目标中,我们将确定SLE患者中存在产生IL-17的CD4+和扩增的DNT细胞-确定临床相关性。在第二部分中,我们将确定糖尿病肾病T细胞的来源是SLE患者,扩增的要求,他们的早期和晚期的信号特征,以及他们对细胞控制机制的敏感性。在第三部分中,我们将确定SLE患者产生TH17的要求。在最后一个目的中,我们研究了在SLE中渗透靶组织的T细胞的性质,并探索了导致不适当归巢的机制。这些研究旨在建议将IL-17作为SLE患者的新治疗靶点,并将产生的信息将提出Th17细胞作为疾病活动的生物标记物。
公共卫生相关性:系统性红斑狼疮困扰着100多万美国人,其中大多数是育龄妇女。诊断经常延误,这种疾病有很高的发病率和死亡率。目前的治疗主要是基于不分青红皂白的免疫抑制。这项提案将确定IL-17作为一种新的治疗靶点,并将产生信息,将Th17细胞作为疾病活动的生物标记物引入。
英文摘要
DESCRIPTION (provided by applicant): Systemic lupus erythematosus afflicts 1 to 2 million Americans and is associated with significant morbidity and mortality. While wise use of steroids and cytotoxics drugs along with effective use of antibiotics overall survival and quality of life have increased significantly over the last 30 years, we still lack specific treatment, and among others, the lack of full understanding of involved pathogenic mechanisms and of proper disease biomarkers are to be blamed for this. Immune cell and cytokine abnormalities in patients with systemic lupus erythematosus (SLE) are diverse and involve among others decreased cytotoxic responses, decreased activation induced cell death, decreased T regulatory function, increased dendritic cell function, increased IFNa, IL-6 and decreased IL-2, IFN? and TNFa production. Distinct molecular and biochemical abnormalities may account for several cell and cytokine abnormalities. Among peripheral T cells an expanded population of T cells missing CD4 and CD8 from the surface (double negative (DN) T cells exists which when placed in coculture with autologous B cells promoted the production of immunoglobulin and anti-dsDNA. We have recently found that this DN T cell population in SLE patients can be expanded in vitro and that it produces IL- 17 and more importantly, IL-17 producing DN T cells infiltrated kidney tissue of patients with lupus nephritis. We propose, accordingly, that an expanded DN T cell population in patients with SLE produces IL-17 and participates in target organ damage. We will test our thesis in experiments outlined in this application and grouped in four specific aims: In the first aim we will establish the presence of CD4+ and expanded DN T cells producing IL-17 in patients with SLE-determine clinical correlations. In the second we will determine the origin of DN T cells is SLE patients, the requirements for expansion, their early and late signaling profile and their susceptibility to cellular control mechanisms. In the third we will determine the requirements for the generation of TH17 in SLE. In the last aim we study the nature of T cells that infiltrate target tissues in SLE and explore mechanisms which are responsible for the inappropriate homing. These studies intend to propose IL-17 as a novel treatment target in SLE patients and will generate information which will propose Th17 cells as a biomarker of disease activity.
PUBLIC HEALTH RELEVANCE: Systemic lupus erythematosus afflicts more than one million Americans most of whom are women in the child bearing age. Diagnosis is frequently delayed and the disease has significant morbidity and mortality. Current treatment is based primarily on indiscriminate immunosuppression. This proposal will identify IL-17 as a novel treatment target and will generate information to introduce Th17 cells as a biomarker of disease activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
T cells in Lupus
-
批准号:10308697
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2019
-
负责人:George C Tsokos
-
依托单位:
T cells in Lupus
-
批准号:10533282
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2019
-
负责人:George C Tsokos
-
依托单位:
T cells in Lupus
-
批准号:10063477
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2019
-
负责人:George C Tsokos
-
依托单位:
Phosphatases in Systemic Autoimmunity
-
批准号:10468134
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2018
-
负责人:George C Tsokos
-
依托单位:
Phosphatases in Systemic Autoimmunity
-
批准号:10000837
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2018
-
负责人:George C Tsokos
-
依托单位:
Phosphatases in Systemic Autoimmunity
-
批准号:10242137
-
项目类别:
-
资助金额:$43.75万
-
财政年份:2018
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:9247888
-
项目类别:
-
资助金额:$35.94万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:8640886
-
项目类别:
-
资助金额:$36.03万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:8480535
-
项目类别:
-
资助金额:$37.62万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Targeting CaMK4 in SLE
-
批准号:9040093
-
项目类别:
-
资助金额:$35.97万
-
财政年份:2013
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8453448
-
项目类别:
-
资助金额:$40.48万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8653524
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8066298
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded Double Negative T cells in SLE.
-
批准号:10620721
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded Double Negative T cells in SLE.
-
批准号:10295607
-
项目类别:
-
资助金额:$52.36万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded double negative T cells in SLE
-
批准号:8259759
-
项目类别:
-
资助金额:$43.07万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
Expanded Double Negative T cells in SLE.
-
批准号:10424576
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2010
-
负责人:George C Tsokos
-
依托单位:
CIS School in Systemic Autoimmune Diseases
-
批准号:7664206
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2009
-
负责人:George C Tsokos
-
依托单位:
CIS School in Systemic Autoimmune Diseases
-
批准号:7800479
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2009
-
负责人:George C Tsokos
-
依托单位:
CIS School in Systemic Autoimmune Diseases
-
批准号:7484755
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2008
-
负责人:George C Tsokos
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: